TradesZ
Top 10 stocks to add now
← All stocks
NNNN

NNNN — Anbio Biotechnology

CIK 1982708 · SEC EDGAR fundamentals

Headline figures

Revenue
$6.7M
-71.5% vs prior year

Top-line sales for the most-recent fiscal year

FY2025 · 20-F

Net income
$2.3M
-77.5% vs prior year

Profit after all expenses, taxes, interest

FY2025 · 20-F

EPS (diluted)
$0.10
-100.0% vs prior year

Net income per diluted share outstanding

FY2025 · 20-F

Op. cashflow
$898K
-79.8% vs prior year

Cash actually generated by the business

FY2025 · 20-F

Balance sheet

Total assets
$18.9M

Everything the company owns

FY2025 · 20-F

Total liabilities
$1.7M

Everything the company owes

FY2025 · 20-F

Stockholders equity
$12.5M

Assets minus liabilities (book value)

FY2025 · 20-F

Long-term debt
—

Debt due more than 12 months out

Revenue history

Revenues · FY values from Revenues

Fiscal year Revenue vs prior Source
FY2025 $6.7M -71.5% 20-F
FY2024 $23.5M — 20-F

Data sources & methodology

All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →

TZ Researched & published by TradesZ Research

Not investment advice. Figures sourced from the SEC's XBRL CompanyFacts API — public-domain federal records. Companies occasionally restate prior-year numbers; we show the latest filed value per fiscal year.